Chaker Aloui

Chaker Aloui

Auto-generated profile, based on publicly available information

Chaker Aloui

GIMAP-EA3064, University of Lyon, Saint-Etienne, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CAChaker Aloui
Chaker Aloui
APAntoine Prigent
Antoine Prigent
CSCaroline Sut
Caroline Sut
STSofiane Tariket
Sofiane Tariket
HHHind Hamzeh-Cognasse
Hind Hamzeh-Cognasse
OGOlivier Garraud
Olivier Garraud
The CD40 ligand (CD40L) is a transmembrane molecule of crucial interest in cell signaling in innate and adaptive immunity. It is expressed by a variety of cells, but mainly by activated T-lymphocytes and platelets. CD40L may be cleaved into a soluble form (sCD40L) that has a cytokine-like activity. Both forms bind to several receptors, including CD40. This interaction is necessary for the antigen specific immune response. Furthermore, CD40L and sCD40L are involved in inflammation and a panoply of immune related and vascular pathologies. Soluble CD40L is primarily produced by platelets after activation, degranulation and cleavage, which may present a problem for transfusion. Soluble CD40L is involved in adverse transfusion events including transfusion related acute lung injury (TRALI). Although platelet storage designed for transfusion occurs in sterile conditions, platelets are activated and release sCD40L without known agonists. Recently, proteomic studies identified signaling pathways activated in platelet concentrates. Soluble CD40L is a good candidate for platelet activation in an auto-amplification loop. In this review, we describe the immunomodulatory role of CD40L in physiological and pathological conditions. We will focus on the main signaling pathways activated by CD40L after binding to its different receptors.

29 November 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
OGOlivier Garraud
Olivier Garraud
STS. Tariket
S. Tariket
CSC. Sut
C. Sut
AHA. Haddad
A. Haddad
CAC. Aloui
C. Aloui
FCFabrice Cognasse
Fabrice Cognasse
Transfusion of blood cell components is frequent in the therapeutic arsenal; it is globally safe or even very safe. At present, residual clinical manifestations are principally inflammatory in nature. If some rare clinical hazards manifest as acute inflammation symptoms of various origin, most of them linked with conflicting and undesirable biological material accompanying the therapeutic component (infectious pathogen, pathogenic antibody, unwanted antigen, or allergen), the general feature is subtler and less visible, and essentially consists of alloimmunization or febrile non-hemolytic transfusion reaction. The present essay aims to present updates in hematology and immunology that help understand how, when, and why subclinical inflammation underlies alloimmunization and circumstances characteristic of red blood cells and – even more frequently – platelets that contribute inflammatory mediators. Modern transfusion medicine makes sustained efforts to limit such inflammatory hazards; efforts can be successful only if one has a clear view of each element’s role.

27 February 2018 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
CSCaroline Sut
Caroline Sut
STSofiane Tariket
Sofiane Tariket
CACécile Aubron
Cécile Aubron
CAChaker Aloui
Chaker Aloui
HHHind Hamzeh-Cognasse
Hind Hamzeh-Cognasse
FCFabrice Cognasse
Fabrice Cognasse
Platelets transfusion is a safe process, but during or after the process, the recipient may experience an adverse reaction and occasionally a serious adverse reaction (SAR). In this review, we focus on the inflammatory potential of platelet components (PCs) and their involvement in SARs. Recent evidence has highlighted a central role for platelets in the host inflammatory and immune responses. Blood platelets are involved in inflammation and various other aspects of innate immunity through the release of a plethora of immunomodulatory cytokines, chemokines, and associated molecules, collectively termed biological response modifiers that behave like ligands for endothelial and leukocyte receptors and for platelets themselves. The involvement of PCs in SARs—particularly on a critically ill patient’s context—could be related, at least in part, to the inflammatory functions of platelets, acquired during storage lesions. Moreover, we focus on causal link between platelet activation and immune-mediated disorders (transfusion-associated immunomodulation, platelets, polyanions, and bacterial defense and alloimmunization). This is linked to the platelets’ propensity to be activated even in the absence of deliberate stimuli and to the occurrence of time-dependent storage lesions.

7 October 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
FCFabrice Cognasse
Fabrice Cognasse
CAChaker Aloui
Chaker Aloui
KNKim Anh Nguyen
Kim Anh Nguyen
HHHind Hamzeh-Cognasse
Hind Hamzeh-Cognasse
JFJocelyne Fagan
Jocelyne Fagan
OGOlivier Garraud
Olivier Garraud

1 May 2018 in Transfusion Clinique et Biologique
Verified
Journal Article
Closed access
OGOlivier Garraud
Olivier Garraud
CSC. Sut
C. Sut
AHA. Haddad
A. Haddad
STS. Tariket
S. Tariket
CAC. Aloui
C. Aloui
GAG. Andreu
G. Andreu

20 April 2016 in Scientific Reports
Verified
Journal Article
Open access
CAChaker Aloui
Chaker Aloui
APAntoine Prigent
Antoine Prigent
STSofiane Tariket
Sofiane Tariket
CSCaroline Sut
Caroline Sut
JFJocelyne Fagan
Jocelyne Fagan
SLSandrine Laradi
Sandrine Laradi
Increased circulating soluble CD40 ligand (sCD40L) is commonly associated with inflammatory disorders. We aimed to investigate whether gene polymorphisms in CD40LG, CD40 and ITGA2 are associated with a propensity to secrete sCD40L; thus, we examined this issue at the level of human platelets, the principal source of sCD40L. We performed single polymorphism and haplotype analyses to test for the effect of twelve polymorphisms across the CD40LG, CD40 and ITGA2 genes in blood donors. ITGA2 presented a positive association with rs1126643, with a significant modification in sCD40L secretion (carriers of C allele, P = 0.02), unlike the investigated CD40LG and CD40 polymorphisms. One CD40LG haplotype (TGGC) showing rs975379 (C/T), rs3092952 (A/G), rs3092933 (A/G) and rs3092929 (A/C) was associated with increased sCD40L levels (1.906 μg/L (95% CI: 1.060 to 2.751); P = 0.000009). The sCD40L level was associated with the inter-chromosomal CD40LG/CD40/ITGA2 haplotype (ATC), displaying rs3092952 (A/G), rs1883832 (C/T) and rs1126643 (C/T), with increased sCD40L levels (P = 0.0135). Our results help to decipher the genetic role of CD40LG, CD40 and ITGA2 with regard to sCD40L levels found in platelet components. Given the crucial role of sCD40L, this haplotype study in a transfusion model may be helpful to further determine the role of haplotypes in inflammatory clinical settings.